2023
Overall survival in low-comorbidity patients with stage I non–small cell lung cancer who chose stereotactic body radiotherapy compared to surgery
Udelsman B, Canavan M, Zhan P, Ely S, Park H, Boffa D, Mase V. Overall survival in low-comorbidity patients with stage I non–small cell lung cancer who chose stereotactic body radiotherapy compared to surgery. Journal Of Thoracic And Cardiovascular Surgery 2023, 167: 822-833.e7. PMID: 37500052, DOI: 10.1016/j.jtcvs.2023.07.021.Peer-Reviewed Original ResearchNon-small cell lung cancerStereotactic body radiotherapyStage I non-small cell lung cancerLow-comorbidity patientsCell lung cancerOverall survivalSurgical managementLung cancerSurgical resectionBody radiotherapyClinical stage I non-small cell lung cancerEarly-stage non-small cell lung cancerPropensity score-matched cohortPropensity score-matched patientsPropensity score-matched analysisEarly-stage lung cancerLong-term OSNational Cancer DatabaseProportion of patientsCancer DatabasePatientsSBRT patientsSurgeryCancerMortality
2022
Utilization and Survival Impact of Hypofractionated Radiotherapy in Stage I Non-small Cell Lung Cancer
Saeed N, Jin L, Amini A, Verma V, Lester-Coll N, Chen P, Decker R, Park H. Utilization and Survival Impact of Hypofractionated Radiotherapy in Stage I Non-small Cell Lung Cancer. American Journal Of Clinical Oncology 2022, 46: 66-72. PMID: 36662872, DOI: 10.1097/coc.0000000000000974.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerStage I non-small cell lung cancerOverall survivalCell lung cancerLung cancerStereotactic body radiation therapyNational Cancer DatabaseLog-rank testBody radiation therapyOptimal fractionation scheduleMultivariable modeling techniquesOS benefitHypofractionated radiotherapySurvival impactMultivariable analysisCox regressionCancer DatabaseRetrospective analysisFractionation schedulesRadiation therapyHFRTPatientsCFRTRadiotherapyKaplan-Meier estimator
2020
Thermal ablation versus stereotactic body radiotherapy for stage I non-small cell lung cancer: A cost-effectiveness analysis.
Wu X, Uhlig J, Blasberg J, Gettinger S, Suh R, Solomon S, Kim K. Thermal ablation versus stereotactic body radiotherapy for stage I non-small cell lung cancer: A cost-effectiveness analysis. Journal Of Clinical Oncology 2020, 38: e21061-e21061. DOI: 10.1200/jco.2020.38.15_suppl.e21061.Peer-Reviewed Original ResearchNon-small cell lung cancerStereotactic body radiotherapyIncremental cost-effectiveness ratioStage I non-small cell lung cancerOne-way sensitivity analysesCell lung cancerBody radiotherapyRecurrence riskLung cancerHealth benefitsStage I NSCLC patientsLong-term prospective trialsPerfect healthAnnual recurrence riskHealth care sector perspectiveShort-term complicationsSensitivity analysisLong-term surveillanceThermal ablationWeeks of lifeCost-effectiveness analysisCost-effectiveness ratioDeterministic sensitivity analysesMedicare billing dataMultiple sensitivity analysesManagement of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic CHEST Expert Panel Report
Mazzone PJ, Gould MK, Arenberg DA, Chen AC, Choi HK, Detterbeck FC, Farjah F, Fong KM, Iaccarino JM, Janes SM, Kanne JP, Kazerooni EA, MacMahon H, Naidich DP, Powell CA, Raoof S, Rivera MP, Tanner NT, Tanoue LK, Tremblay A, Vachani A, White CS, Wiener RS, Silvestri GA. Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic CHEST Expert Panel Report. CHEST Journal 2020, 158: 406-415. PMID: 32335067, PMCID: PMC7177089, DOI: 10.1016/j.chest.2020.04.020.Peer-Reviewed Original ResearchConceptsLung cancer screeningStage I non-small cell lung cancerNon-small cell lung cancerCell lung cancerCancer screeningLung nodule evaluationConsensus statementLung nodulesLung cancerClinical stage I non-small cell lung cancerNodule evaluationAnnual lung cancer screeningHigh-risk lung nodulesLung cancer screening programsCHEST Expert Panel ReportCurrent guideline recommendationsCancer screening programsPatient-related factorsCommon clinical scenariosCoronavirus disease 2019Balance of benefitsIndividual patient careCOVID-19 pandemicExpert Panel ReportPotential exposureManagement of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic: CHEST Expert Panel Report
Mazzone PJ, Gould MK, Arenberg DA, Chen AC, Choi HK, Detterbeck FC, Farjah F, Fong KM, Iaccarino JM, Janes SM, Kanne JP, Kazerooni EA, MacMahon H, Naidich DP, Powell CA, Raoof S, Rivera MP, Tanner NT, Tanoue LK, Tremblay A, Vachani A, White CS, Wiener RS, Silvestri GA. Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic: CHEST Expert Panel Report. Radiology Imaging Cancer 2020, 2: e204013. PMID: 33778716, PMCID: PMC7233408, DOI: 10.1148/rycan.2020204013.Peer-Reviewed Original ResearchConceptsLung cancer screeningStage I non-small cell lung cancerNon-small cell lung cancerCell lung cancerCancer screeningLung nodule evaluationConsensus statementLung nodulesLung cancerClinical stage I non-small cell lung cancerNodule evaluationAnnual lung cancer screeningHigh-risk lung nodulesLung cancer screening programsCurrent guideline recommendationsCancer screening programsPatient-related factorsCommon clinical scenariosCoronavirus disease 2019Balance of benefitsIndividual patient careCOVID-19 pandemicPotential exposureGuideline recommendationsSurveillance imaging
2016
Surveillance Practice Patterns after Curative Intent Therapy for Stage I Non-Small-Cell Lung Cancer in the Medicare Population
Erb CT, Su KW, Soulos PR, Tanoue LT, Gross CP. Surveillance Practice Patterns after Curative Intent Therapy for Stage I Non-Small-Cell Lung Cancer in the Medicare Population. Lung Cancer 2016, 99: 200-207. PMID: 27565940, PMCID: PMC5003420, DOI: 10.1016/j.lungcan.2016.07.017.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerStage I non-small cell lung cancerCurative-intent therapyCell lung cancerLung cancerPractice patternsMedicare populationEarly-stage non-small cell lung cancerStage non-small cell lung cancerPositron emission tomography scanRoutine imaging surveillanceSpecialty society recommendationsPercent of patientsEmission tomography scanEvidence-based guidelinesRecent practice patternsMore comorbiditiesGuideline adherenceImaging surveillanceProvider factorsSociety guidelinesSurveillance guidelinesSurveillance imagingPrimary carePrimary treatmentLobectomy versus stereotactic body radiotherapy in healthy patients with stage I lung cancer
Rosen JE, Salazar MC, Wang Z, Yu JB, Decker RH, Kim AW, Detterbeck FC, Boffa DJ. Lobectomy versus stereotactic body radiotherapy in healthy patients with stage I lung cancer. Journal Of Thoracic And Cardiovascular Surgery 2016, 152: 44-54.e9. PMID: 27131846, DOI: 10.1016/j.jtcvs.2016.03.060.Peer-Reviewed Original ResearchConceptsStage I lung cancerStereotactic body radiotherapyI lung cancerNational Cancer DatabaseClinical stage I lung cancerNon-small cell lung cancerCell lung cancerBody radiotherapyHealthy patientsLung cancerCancer DatabaseClinical stage I non-small cell lung cancerStage I non-small cell lung cancerBetter outcomesEarly-stage non-small cell lung cancerPatient healthCox proportional hazards modelComorbidity-free patientsClinical stage IPropensity-matched analysisProportional hazards modelLong-term survivalHealth-related reasonsStereotactic patientsT1N0M0 tumorsResection is safe for patients with stage IIIA NSCLC undergoing multimodality therapy
Lushaj E, Julliard W, Bretl T, Badami A, Macke R, Blasberg J, Maloney J. Resection is safe for patients with stage IIIA NSCLC undergoing multimodality therapy. Cancer Treatment And Research Communications 2016, 5: 22-25. DOI: 10.1016/j.ctrc.2015.12.002.Peer-Reviewed Original ResearchNon-small cell lung cancerIIIA non-small cell lung cancerStage IIIA non-small cell lung cancerStage I non-small cell lung cancerVideo-assisted thoracoscopic surgeryStage IIIA patientsIIIA patientsStage IStage IIMultimodality therapySurvival rateMedian hospital lengthOverall survival rateResults Mean ageCell lung cancerPost-treatment survivalInitial therapyAdvanced diseaseHospital lengthNeoadjuvant radiationPerioperative morbidityPulmonary resectionThoracoscopic surgeryOptimal therapySurgical intervention
2015
Survival Comparison of 3 Versus 4-5 Fractions for Stereotactic Body Radiation Therapy in Stage I Non-Small Cell Lung Cancer
Park H, Corso C, Rutter C, Kim A, Yu J, Husain Z, Decker R. Survival Comparison of 3 Versus 4-5 Fractions for Stereotactic Body Radiation Therapy in Stage I Non-Small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2015, 93: s100. DOI: 10.1016/j.ijrobp.2015.07.240.Peer-Reviewed Original ResearchHigher Facility Case Volume of Stereotactic Body Radiation Therapy Is Associated With Improved Overall Survival in Clinical Stage I Non-Small Cell Lung Cancer
Park H, Wang E, Corso C, Rutter C, Wilson L, Kim A, Gross C, Yu J, Decker R. Higher Facility Case Volume of Stereotactic Body Radiation Therapy Is Associated With Improved Overall Survival in Clinical Stage I Non-Small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2015, 93: s186-s187. DOI: 10.1016/j.ijrobp.2015.07.447.Peer-Reviewed Original Research
2014
Surveillance Practice Patterns After Curative Intent Therapy for Stage I Non-small Cell Lung Cancer in the Medicare Population
Erb C, Soulos P, Tanoue L, Gross C. Surveillance Practice Patterns After Curative Intent Therapy for Stage I Non-small Cell Lung Cancer in the Medicare Population. CHEST Journal 2014, 146: 607a. DOI: 10.1378/chest.1992085.Peer-Reviewed Original ResearchStage I non-small cell lung cancerNon-small cell lung cancerCurative-intent therapyCell lung cancerLung cancerPractice patternsMedicare populationTherapyCancerComparative Effectiveness of Stereotactic Body Radiation Therapy Versus Surgery for Stage I Non-small Cell Lung Cancer
Yu J, Soulos P, Cramer L, Decker R, Kim A, Gross C. Comparative Effectiveness of Stereotactic Body Radiation Therapy Versus Surgery for Stage I Non-small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s138. DOI: 10.1016/j.ijrobp.2014.05.596.Peer-Reviewed Original ResearchStage I non-small cell lung cancerNon-small cell lung cancerCell lung cancerVersus SurgeryLung cancerComparative effectivenessSurgeryCancerIncrease in the use of lung stereotactic body radiotherapy without a preceding biopsy in the United States
Rutter CE, Corso CD, Park HS, Mancini BR, Yeboa DN, Lester-Coll NH, Kim AW, Decker RH. Increase in the use of lung stereotactic body radiotherapy without a preceding biopsy in the United States. Lung Cancer 2014, 85: 390-394. PMID: 25001510, DOI: 10.1016/j.lungcan.2014.06.013.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerStereotactic body radiotherapyBody radiotherapyStage I non-small cell lung cancerEarly-stage non-small cell lung cancerStage non-small cell lung cancerMultivariate analysisUse of SBRTLung stereotactic body radiotherapyLogistic regressionNational Cancer DatabasePercentage of patientsYear of diagnosisSmaller tumor sizeCell lung cancerMultivariate logistic regressionMedical inoperabilityMedical comorbiditiesInoperable patientsTumor sizeLung cancerCancer DatabaseEfficacious treatmentSBRT deliveryBiopsy
2013
Use of New Treatment Modalities for Non-small Cell Lung Cancer Care in the Medicare Population
Vest MT, Herrin J, Soulos PR, Decker RH, Tanoue L, Michaud G, Kim AW, Detterbeck F, Morgensztern D, Gross CP. Use of New Treatment Modalities for Non-small Cell Lung Cancer Care in the Medicare Population. CHEST Journal 2013, 143: 429-435. PMID: 23187634, PMCID: PMC3566996, DOI: 10.1378/chest.12-1149.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerStage I non-small cell lung cancerVideo-assisted thoracoscopic surgeryProportion of patientsOlder patientsCancer careNon-small cell lung cancer careEarly-stage non-small cell lung cancerStage non-small cell lung cancerEnd Results-Medicare databaseLung cancer careCell lung cancerCurative local therapyNew treatment modalitiesOverall useNew surgical techniqueType of treatmentNew radiation modalitiesRadiation therapy modalitiesSurgical resectionCurative therapyLocal therapyMore patientsThoracoscopic surgeryMean age
2012
American College of Chest Physicians and Society of Thoracic Surgeons Consensus Statement for Evaluation and Management for High-Risk Patients With Stage I Non-small Cell Lung Cancer
Donington J, Ferguson M, Mazzone P, Handy J, Schuchert M, Fernando H, Loo B, Lanuti M, de Hoyos A, Detterbeck F, Pennathur A, Howington J, Landreneau R, Silvestri G, Surgeons F. American College of Chest Physicians and Society of Thoracic Surgeons Consensus Statement for Evaluation and Management for High-Risk Patients With Stage I Non-small Cell Lung Cancer. CHEST Journal 2012, 142: 1620-1635. PMID: 23208335, DOI: 10.1378/chest.12-0790.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerStage I non-small cell lung cancerHigh-risk patientsCell lung cancerChest PhysiciansTreatment optionsLung cancerAmerican CollegeStereotactic body radiation therapySevere medical comorbiditiesThoracic Oncology NetworkAlternative treatment optionMore indolent tumorsBody radiation therapyRisk-benefit decisionsInterventional riskMedical comorbiditiesNonoperative therapyRespiratory failureInvolved lobeMediastinal lymphProcedural morbidityRegional recurrenceSublobar resectionRadiographic staging
2011
Management of Early Stage Non–Small Cell Lung Cancer in High-Risk Patients
Donington JS, Blasberg JD. Management of Early Stage Non–Small Cell Lung Cancer in High-Risk Patients. Thoracic Surgery Clinics 2011, 22: 55-65. PMID: 22108689, DOI: 10.1016/j.thorsurg.2011.08.018.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerEarly-stage non-small cell lung cancerHigh-risk patientsCell lung cancerLung cancerStage I non-small cell lung cancerStage non-small cell lung cancerPeri-procedural morbidityOperable lung cancerType of resectionRefinement of indicationsAnatomic resectionMediastinal lymphSublobar resectionOncologic efficacyTreatment optionsPreferred treatmentResectionPatientsCancerTreatmentLobectomyLymphMorbidityMortality
2010
Sublobar Resection: A Movement from the Lung Cancer Study Group
Blasberg JD, Pass HI, Donington JS. Sublobar Resection: A Movement from the Lung Cancer Study Group. Journal Of Thoracic Oncology 2010, 5: 1583-1593. PMID: 20879185, DOI: 10.1097/jto.0b013e3181e77604.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerSublobar resectionStage IA non-small cell lung cancerStage I non-small cell lung cancerMulti-institutional phase III trialLung Cancer Study GroupPostoperative lung functionSingle-institution trialLung cancer resectionCancer Study GroupHigh-risk patientsPhase III trialsEarly-stage diseaseInvasive surgical resectionCell lung cancerHigh-risk individualsMultislice computer tomographyRate of survivalPerioperative morbidityIII trialsSurgical resectionCancer resectionLung functionOncologic effectivenessRecurrence rate
2007
Invasive Mediastinal Staging of Lung Cancer ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Detterbeck FC, Jantz MA, Wallace M, Vansteenkiste J, Silvestri GA. Invasive Mediastinal Staging of Lung Cancer ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition). CHEST Journal 2007, 132: 202s-220s. PMID: 17873169, DOI: 10.1378/chest.07-1362.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerLymph nodesInvasive stagingMediastinal nodesClinical stage I non-small cell lung cancerLung Cancer ACCP Evidence-Based Clinical Practice GuidelinesACCP Evidence-Based Clinical Practice GuidelinesStage I non-small cell lung cancerNeedle techniqueEvidence-based clinical practice guidelinesLeft upper lobe tumorsNormal-sized lymph nodesPositron emission tomography scanningPET scan findingsUpper lobe tumorsMediastinal lymph nodesCell lung cancerClinical practice guidelinesStaging of patientsInvasive mediastinal stagingHigher FN rateInvasive confirmationMediastinal infiltrationNode enlargementScan findings
2005
Tumor Cavitation in Stage I Non–Small Cell Lung Cancer: Epidermal Growth Factor Receptor Expression and Prediction of Poor Outcome
Onn A, Choe DH, Herbst RS, Correa AM, Munden RF, Truong MT, Vaporciyan AA, Isobe T, Gilcrease MZ, Marom EM. Tumor Cavitation in Stage I Non–Small Cell Lung Cancer: Epidermal Growth Factor Receptor Expression and Prediction of Poor Outcome. Radiology 2005, 237: 342-7. PMID: 16183941, DOI: 10.1148/radiol.2371041650.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellErbB ReceptorsFemaleFollow-Up StudiesHumansImmunohistochemistryLung NeoplasmsMaleMiddle AgedNeoplasm StagingPrognosisProportional Hazards ModelsRadiography, ThoracicReceptor, ErbB-2Retrospective StudiesSurvival RateTomography, X-Ray ComputedConceptsStage I non-small cell lung cancerNon-small cell lung cancerEpidermal growth factor receptorCell lung cancerSquamous cell carcinomaCavitary lesionsTumor diameterCell carcinomaLung cancerSurvival timePathologic stage I non-small cell lung cancerEGFR overexpressionProportional hazards regression modelsShorter disease-free survival timeShorter overall survival timeDisease-free survival timeEpidermal growth factor receptor expressionFindings of chestGrowth factor receptor expressionMedian overall survivalOverall survival timeHazards regression modelsPresence of calcificationFactor receptor expressionInstitutional review board
2004
Synchronous Overexpression of Epidermal Growth Factor Receptor and HER2-neu Protein Is a Predictor of Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer
Onn A, Correa AM, Gilcrease M, Isobe T, Massarelli E, Bucana CD, O’Reilly M, Hong WK, Fidler IJ, Putnam JB, Herbst RS. Synchronous Overexpression of Epidermal Growth Factor Receptor and HER2-neu Protein Is a Predictor of Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer. Clinical Cancer Research 2004, 10: 136-143. PMID: 14734462, DOI: 10.1158/1078-0432.ccr-0373-3.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma, Bronchiolo-AlveolarAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellDisease ProgressionErbB ReceptorsFemaleFollow-Up StudiesHumansImmunoenzyme TechniquesLung NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPhosphorylationPrognosisReceptor, ErbB-2Retrospective StudiesRisk FactorsSurvival RateTransforming Growth Factor alphaConceptsStage I non-small cell lung cancerNon-small cell lung cancerEpidermal growth factor receptorCell lung cancerSquamous cell carcinomaHER2-neuGrowth factor alphaPhosphorylated epidermal growth factor receptorGrowth factor receptorCell carcinomaLung cancerFactor alphaPathological stage I non-small cell lung cancerFactor receptorPotential prognostic factorsShorter overall survivalPatients' clinical outcomesSynchronous overexpressionHER2-neu overexpressionLung cancer progressionMaximal therapyMetastatic diseaseOverall survivalPrognostic factorsClinical outcomes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply